Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2018

View Archived Issues

Astellas grants Cardurion license for PDE9 inhibitor with potential in heart failure

Merck & Co. initiates two phase III studies for PCV-15

FDA expands approval of Vonvendi to include perioperative management of bleeding in adults with VWD

Akcea and Ionis complete inotersen licensing transaction

Enanta Pharmaceuticals unveils new compound for HBV infection

Exosomal miRNAs linked to radioresistant lung adenocarcinoma

Theralase updates results from phase Ib study of TLD-1433 in nonmuscle invasive bladder cancer

DSMB recommends continuation of phase I/IIa study of VBI-1901 in recurrent GBM

FDA approves Tavalisse for chronic ITP

Targeting NLRP3 shows promise for NASH and fibrosis

Third endometriosis program enters phase I under Evotec and Bayer alliance

Anavex to initiate phase II trial of ANAVEX2-73 in Parkinson's disease dementia

EPL-1410 demonstrates potential as immune-oncology therapeutic in preclinical models

FDA grants orphan drug designation to KL-1333 for inherited mitochondrial respiratory chain diseases

Asahi Kasei Pharma initates phase III study of isavuconazole for deep-seated mycosis

BioAtla describes activity of anti-ROR2 antibody-drug conjugate BA-3021

GlaxoSmithKline patents novel TrpV4 antagonists

Mission Therapeutics divulges new USP30 inhibitors

Mironid identifies novel PDE4 activators

Pfizer launches Besponsa in Japan

Bayer patents novel IRAK-4 inhibitors

FDA approves Crysvita for X-linked hypophosphatemia in children and adults

New compounds for asthma presented by Sichuan Haisco Pharmaceutical

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.